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http://www.biomedcentral.com/1756-0500/7/688CASE REPORT Open AccessCreatine kinase elevation caused by a
combination of fluvastatin and telmisartan in a
patient heterozygous for the CYP2C9*3 and
ABCC2 -24C > T variants: a case report
Henriette E Meyer zu Schwabedissen1, Werner Siegmund2, Heyo K Kroemer3 and Jens D Rollnik4*Abstract
Background: Genetic factors as predictor of the individual outcome of drug therapy is one aim of personalized
medicine approaches.
Case presentation: We report a drug metabolism based analysis of genetic polymorphisms in a Caucasian patient
receiving fluvastatin and telmisartan experiencing myotoxicity (myalgia and moderate creatine kinase elevation).
Conclusions: The obtained findings suggest that heterocygocity of cytochrome P450 CYP2C9*3 variant in
combination with multidrug resistance-associated protein MRP2 -24C > T functions as risk factor predisposing to
experience drug-drug interaction combing those drugs.
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Drug-drug interactionBackground
Herein we report the case of a patient receiving fluvastatin
for several years developing mild myotoxicity symptoms
after co-administration of telmisartan, an AT1-receptor
antagonist. Importantly, fluvastatin even if exhibiting a ra-
ther modest lipid-lowering effect has been widely recom-
mended for patient receiving pharmacotherapy with high
interaction potential due to the assumed low risk of phar-
macokinetic interaction [1]. It was aim of this retrospect-
ive pharmacogenetic analysis to provide insight into
genetic risk factors for the observed drug-drug inter-
action. In order to identify the predisposing factors the
patient was assessed for frequently occurring single
nucleotide polymorphisms of genes involved in the
pharmacokinetic pathway of fluvastatin and telmisar-
tan, respectively. Based on our current understanding flu-
vastatin is assumed to be taken up into the hepatocyte
mediated by the hepatic uptake transporter organic anion-* Correspondence: prof.rollnik@bdh-klinik-hessisch-oldendorf.de
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article, unless otherwise stated.transporting polypeptide (OATP) OATP1B1, where it ex-
erts its pharmacodynamic action by inhibiting the key
enzyme of hepatic cholesterol synthesis the HMG-CoA
reductase. Subsequent metabolism mediated by the
microsomal cytochrome P450 enzymes especially the
isoform CYP2C9 is the major step of drug elimination.
In addition recent findings indicate that the efflux
transporter BCRP (ABCG2) is also involved in modu-
lating fluvastatin disposition [2,3]. For telmisartan it is
assumed that OATP1B3 is predominantly involved in
hepatic uptake [4], after intrahepatic metabolism medi-
ated by UGTs the telmisartan glucuronide is elimi-
nated via the efflux transporters ABCB1, ABCC2 and
ABCG2 [5]. In addition, Weiss and co-workers re-
ported that telmisartan is a potent inhibitor of ABCG2
and ABCC2 mediated efflux in vitro [6]. Importantly,
recent findings by Cabaleiro et al suggest that pharma-
cokinetics of telmisartan itself is not altered by genetic
variants of CYP2C9 [7], even if telmisartan is an in-
hibitor of this particular enzyme [8].
Every sequential step in the process of hepatic uptake,
metabolism and elimination can serve as subject of druge BioMed Central Ltd. This is an Open Access article distributed under the terms
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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the patient experienced myalgia accompanied by CK ele-
vation after receiving fluvastatin and telmisartan, an
angiotensin II type 1 receptor (AT1) – antagonist.
In order to elucidate the impact of common genetic
variability on the observed drug interaction we deter-
mined well documented impaired function SNPs that
have been associated with fluvastatin kinetics. To our
knowledge this is the first case in the literature describ-
ing in vivo statin side effects in association with an AT1-
receptor blocker.
Most AT1-blockers are metabolized by CYP2C9 [2]. Point
mutations or single-nucleotide polymorphisms (SNPs) in
the CYP2C9 genes have been identified. The most
common coding mutations in CYP2C9 are CYP2C9*2,
and CYP2C9*3 [2]. CYP2C9*2 and CYP2C9*3 differ
from the wild-type CYP2C9*1 by a single point muta-
tion: CYP2C9*2 is characterized by a 430C > T exchange
in exon 3 resulting in an Arg144Cys amino acid substitu-
tion, while CYP2C9*3 is characterized by a 1075A > C
exchange in exon 7 causing an I359L substitution in
the catalytic site of the enzyme [2]. Individuals with




The patient was included in a Pharmacovigilanz Study
initiated by the Department of Pharmacology of the
Ernst Moritz Arndt University in Greifswald. DNA sam-
pling and subsequent genotyping of Genes involved in
pharmacokinetics and -dynamics was approved by the
Ethic Committee of the University Greifswald. DNA was
isolated from peripheral blood cells using a QIAcube.
Purity and content of DNA was assured by NanoDrop®
spectrometry.
Genotyping of CYP2C9*2 (rs1799853) and CYP2C9*3
(rs1057910) variant was performed by duplex pyrose-
quencing. Briefly, the fragments containing the c.430C >
T (CYP2C9*2) or the c.1075A > C polymorphism were
amplified by duplex PCR using the following PCR primers:
5′-GTATTTTGGCCTGAAACCCATA-‵3 (CYP2C9-A2-
sense) , 5′-biotin CACCCTTGGTTTTTCTCAACTC-‵3
(CYP2C9-A2-antisense), 5′-biotin TGCACGAGGTCCA
GAGAT-‵3 (CYP2C9-A3-sense), and 5′-GATACTATGA
ATTTGGGGACTT-‵3 (CYP2C9-A2-antisense). The PCR
resulting in biotinylated amplicons was performed in a
50 μl reaction volume containing 1 x reaction buffer,
0.25 μl Platinum Taq DNA Polymerase (invitrogen),
0.2 mM dNTPs, 1.5 mM MgCl, 40 ng template DNA and
a final concentration of 200 nM of each primer. The PCR
amplification started with an initial denaturation at 95°C
for 15 minutes, followed by 45 cycles of denaturation at
95°C for 45 seconds, annealing at 55°C for 45 seconds,and extension at 72°C for 45 seconds, followed by a
final extension step at 72°C for 5 minutes. Subsequently
the amplified fragments were purified. Briefly, 40 μl of
biotinylated PCR products were incubated with 5 μl
streptavidin-coated sepharose beads (GE Healthcare
Bio-Sciences, Munich Germany) diluted in 35 μl of
PyroMark® Binding Buffer (Qiagen, Hilden Germany).
After 5 minutes incubation biotinylated single stranded
PCR products bound by the beads were isolated using
the PyroMark® Q96 Vacuum Prep Workstation (Qiagen).
After treatment with 50% ethanol, denaturation in 0.2 M
sodiumhydroxid-solution and washing with 10 mM TRIS-
Acetat (pH 7.6) biotinylated single strands were released
into designated wells containing PyroMark® Annealing
Buffer (36 μl) and 4 pmol of sequencing primers 5′-GGG
AAGAGGAGCATTGAGGAC-‵3 (CYP2C9-A2 SEQ)
(CYP2C9-A3 SEQ) and 5′-TGGTGGGGAGAAGGTC-‵3,
followed by a 2 minutes incubation at 80°C. Subsequently,
genotyping was performed using the PSQ 96MA, the
PyroMark® Gold Q96 reagents, and the PSQ 96-Software
(Qiagen). Genotyping of the frequently occurring poly-
morphisms of SLCO1B1, SLCO1B3, SLCO2B1, ABCC2
and ABCG2 was performed using commercially avail-
able TaqMan® SNP Genotyping Assays for SLCO1B1
c.521 T >C (rs4149056), SLCO1B1 c.388A >G (rs2306283),
SLCO1B3 c.699A >G (rs7311358), SLCO2B1 c.935G >A
(rs12422149), SLCO2B1 c.1457C >T (rs2306168), MRP2
(ABCC2), ABCC2 -24C >T (rs717620) ABCC2 c.1294G >A
(rs2273697), ABCC2 c.3972C >T (rs3740066) and ABCG2
c421C>T (rs2231142) (Life Technologies GmbH, Darmstadt,
Germany). After automated DNA extraction from the
blood sample performed as described by the manufacturer
using a QiaCube® (Qiagen, Hilden Germany) the DNA
content was determined photometrically using a Nano-
Drop® (Peqlab, Erlangen Germany). After dilution to
10 ng/μl the DNA sample was stored at -20°C. Genotyping
was performed using the pre-developed TaqMan® SNP
Genotyping Assays (Applied Biosystems, Darmstadt,
Germany). In detail, reactions were carried out in a
5 μl volume containing 1 μl genomic DNA, 0.25 μl
Primer/Probe-Mix, 2.5 μl Genotyping Master Mix and
1.25 μl water (Applied Biosystems). Fluorescence was
assessed for using the Fast Real-Time PCR system 7900
HT (Applied Biosystems) and the Sequence Detection
Software SDS 2.3.
Case report
A 39 year old male patient of Caucasian ethnicity, was
treated for dyslipidemia with 40 mg/d fluvastatin, starting
in January 2006. The patient had only moderately elevated
cholesterol serum levels (total cholesterol 270 mg/dl; LDL
cholesterol 179.8 mg/dl) but had a positive family history
of cardiovascular diseases. Until June 2008, fluvastatin
was combined with the cholesterol absorption inhibitor
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tolerated (lipid levels as well as liver enzymes and creatine
kinase (CK) are displayed in Table 1), the combination
with ezetimibe was discontinued due to gastrointestinal
side effects reported by the patient. During combination
of ezetimibe and fluvastatin, the patient had CK levels
(185-234 U/L) in the upper normal range (CK norm levels
60-175U/L). In September 2008, treatment with the
AT1 blocker telmisartan (20 mg/day) was started due
to borderline hypertension. After 4 weeks of treatment,
the patient complained of mild myalgia, cramps und
fasciculations in the legs. Subsequent testing for CK
revealed an approximately two-fold increase of plasma
levels (229 U/L to 439 U/L) compared to baseline. Tel-
misartan medication was stopped immediately and CK
decreased to normal level 5 days later (145 mg/dl). My-
algia and cramps were no longer reported by the patient.
Anti-hypertensive therapy was changed to candesartan.
Retrospective genotyping of the patient for frequently oc-
curring single nucleotide polymorphisms (SNPs) in genes
previously described to be involved in fluvastatin and tel-
misartan kinetics, was performed respectively (illustrated
in Figure 1). As displayed in Table 2, the patient did not
show genetic variability for the hepatic uptake transporter
OATP1B1 (SLCO1B1 c.388G >A (p.N130D), c.521 T > C
(p.V174A)), OATP1B3 (SLCO1B3 c.699G >A (p.M233I)),
OATP2B1 (SLCO2B1 c. 935G >A (p.R312Q), c.1457C >T
(p.S486F)) and the efflux transporter ABCG2 (c.421C >A
(p.Gln141Lys; rs2231142). However, genotyping of fre-
quently occurring polymorphisms of the major metaboliz-
ing enzyme of fluvastatin namely CYP2C9 revealed that
the patient is heterozygote carrier of the less frequent
occurring SNP located in exon 7 (CYP2C9*3; c.1075A > C
p.Ile359Leu, rs1057910), Figure 2. In addition, the pa-
tient was heterozygote for the -24C > T polymorphism
located in the 5′UTR of the hepatic efflux transporter
ABCC2.Table 1 Lab results and medication of the patient from Janua
Date 01/17/06 02/26/07 05/21/07 11/22/07
Lab parameters:
LDL [mg/dl] 179.8 74.2 71.4 74.4
HDL [mg/dl] 47.0 31.0 49.0 51.0
CK [U/l] n.d. 215 191 223
GGT [U/l] n.d. 29 27 25
Medication:
Fluvastatin - 40 mg/d 40 mg/d 40 mg/d
Ezetimibe - 10 mg/d 10 mg/d 10 mg/d
Telmisartan - - - -
Candesartan - - - -
(CK norm level 60-175U/L).Conclusions
In this report we describe the retrospective genetic ana-
lysis of a patient who experienced mild myalgia and CK
increase after co-administration of fluvastatin with the
AT1- receptor antagonist telmisartan. Findings suggest
that that genetic variability of CYP2C9 in addition to the
ABCC2 (-24C > T) variant might be a risk factor for de-
veloping drug-drug interactions combining fluvastatin
and telmisartan.
Like other exogenous compounds, statin therapy harbours
the risk of rare but significant adverse reactions targeting or-
gans such as muscle (myotoxicity) or liver (transaminase ele-
vation). In particular, the risk of rhabdomyolysis which can
lead to renal failure and death has to be addressed. The find-
ing of a recent report showing that a functional polymorph-
ism in the hepatic uptake transporter OATP1B1 (SLCO1B1)
is the only predictor of simvastatin induced myotoxicity [9]
has given rise to several studies focussing on effects of this
particular polymorphism on statin disposition [10].
In general, fluvastatin undergoes extensive fist pass
metabolism resulting in a bioavailability of only 19-29%.
In addition, the majority of fluvastatin is eliminated as
metabolites into the bile, and it has been suggested that
CYP2C9 accounts for 50-80% of fluvastatin metabolism,
whereas CYP2C8 and CYP3A4 play only a minor role.
In line with this finding it has been shown that impaired
function alleles of CYP2C9 are associated with changes
in fluvastatin disposition and efficacy in healthy volun-
teers [11]. In particular, CYP2C9 exhibits commonly
occurring SNPs, namely the CYP2C9*2 (c.430 C > T;
p.Arg144Cys; rs1799853) variant, which is frequent
among Caucasians with approximately 1% of the popula-
tion being homozygous carriers and 22% heterozygous,
whereas the corresponding figures for the CYP2C9*3
(c.1075A > C p.Ile359Leu, rs1057910) allele in a Caucasian
population are much lower with only 0.4% and 15%, re-
spectively [6]. Especially the CYP2C9*3 allele, which isry 2006 until November 2009
03/07/08 06/27/08 10/17/08 10/22/08 11/18/09
- 87.6 117.8 - 137.6
- 52.0 48.0 - 46.0
234 229 439 145 212
22 20 25 - 36
40 mg/d 40 mg/d 40 mg/d 40 mg/d 40 mg/d
10 mg/d - - - -
- - 20 mg/d - -















Figure 1 Illustration of fluvastatin and telmisartan pharmacokinetics. Drug transporters and metabolizing enzymes involved in the
heptaocellular handling of fluvastatin and telmisartan are depicted. Transporters in black are more likely subject of drug drug interactions.
UGT uridine diphosphate glucuronosyltransferase
Table 2 Genotyping results of the patient for genes
implicated in drug disposition of fluvastatin and/or
telmisartan











OATP2B1 Cellular uptake of
telmisartan.
SLCO2B1 c. 935G>A GG
SLCO2B1 c.1457C>T CC
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exon 7 and results in an amino acid exchange in the cata-
lytic site of the enzyme has been previously shown to
result in impaired metabolism of substrate drugs [12].
However, the effect of genetic variants on catalytic ac-
tivity and the clinical impact seems to be substrate
specific.
Genotyping for the above described polymorphisms in
CYP2C9 revealed that the patient was heterozygous for
CYP2C9*3 allele, suggesting that the patient carries a pre-
disposition for higher fluvastatin plasma levels, which
could contribute to increased susceptibility for adverse
side effects. However, the history of the patient shows that
the CYP2C9*3 variant alone was not the only factor in-
ducing myalgia and CK elevation, which began after
co-administration of telmisartan. This is in accordance
with the previously described lack of association of genetic
variants of CYP2C9 variants with fluvastatin induced myo-
toxicity. However, it should be noted that only one patient
was carrier of the CYP2C9*3 variant in this report [13].
Based on the current understanding of telmisartan
pharmacokinetics, the drug-drug interaction described
in our patient could involve additional mechanisms es-
pecially as telmisartan is only a moderate CYP2C9 in-
hibitor [7,8]. However, in individuals harbouring a low
function allele of CYP2C9 in heterocygocity, the inhibitory
capacity might be of clinical significance. Taken together,
the importance of otherwise non-significant pharmaco-
kinetic drug-drug interaction in the presence of phar-
macokinetic variant alleles like CYP2C9*3 merits further
discussion.
However, the majority of telmisartan is assumed to be









Figure 2 Result of cytochrome P450 CYP2C9 genotyping of the patient in comparison to a control sample.
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and MDR1 (ABCB1) [8]. Testing the influence of fre-
quently occurring SNPs in ABCB1 and ABCC2 revealed
an impact of the ABCC2 -24C >T variant on telmisartan
disposition [9,10]. Considering the inhibitory capacity of
telmisartan on CYP2C9 mediated catalysis, which had
been identified in vitro by Kamiyama and co-workers
(IC50 41.9 ± 15.1 μM)., the identified heterocygocity of
the patient for the MRP2 -24C > T allele gives reason
for the speculation of this polymorphism being involved
in the susceptibility of the herein described drug-drug
interaction. However, Kamiyama and co-workers who
conducted the in vitro study, suggested that due to the
high Ki in association with relatively low free plasma levels
of telmisartan would be unlikely to exert clinically relevant
inhibition of CYP2C9 [8]. In accordance with those find-
ings are results from an in vivo study showing that telmi-
sartan did not influence the plasma levels and efficacy
(INR) of warfarin another CYP2C9 substrate [14].
However, we assume that the prevalence of both pre-
disposing factors reduced hepatic elimination of telmi-
sartan in association with reduced hepatic metabolism offluvastatin, resulted in the herein described drug-drug
interaction. This report further strengthens the hypoth-
esis that the success of “personalized medicine” in terms
of genotype driven risk stratifications are not sufficiently
supported by monogenetic pharmacological analyses,
which are commonly conducted [15]. This case illus-
trates that a combination of both – pharmacogenomics
and the knowledge of drug-drug interactions – could
help to achieve better clinical outcomes by personal-
ized medicine.
Consent
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